Global Institute Of Stem Cell Therapy And Research

Archives

Author's Posts

New research demonstrates that vitamin C targets and kills cancer stem cells, the cells responsible for cancer tumors growing and spreading. Researchers at the U.K.’s University of Salford found that vitamin C — ascorbic acid — was up to 10 times more effective in stopping cancer than experimental treatments.

“We have been looking at how to target cancer stem cells with a range of natural substances, but by far the most exciting are the results with vitamin C,” said Dr. Michael P. Lisanti.

Cancer stem-like cells are thought to be resistant to chemotherapy, which leads to treatment failure in patients with advanced disease. Researchers also believe that cancer stem cells (CSC) trigger the recurrence of tumors and fuel their growth. This allows them to spread throughout the body and cause death.

The Salford scientists set out to evaluate the bioenergetics of cancer stem cells — the processes which allow the cells to live and thrive — with the intent of disrupting their metabolism.

They studied the impact of seven substances: the clinically-approved epilepsy drug stiripentol, three natural products — caffeic acid phenethyl ester (CAPE), silibinin and ascorbic acid — and experimental pharmaceuticals actinonin, FK866 and 2-DG.

While they found that natural antibiotic actinonin and the compound FK866 were the most potent, the natural products also inhibited the formation of cancer stem cells, with vitamin C outperforming 2-DG 10-fold in terms of potency.

“Controlling cancer stem cells is the only way to control cancer and is a major weapon against metastatic cancer, which is the main killer of cancer patients,” neurosurgeon Dr. Russell Blaylock tells Newsmax Health.

“Conventional chemo and radiation can cure or control only 5 to 10 percent of metastatic cancers,” says Blaylock, author of Dr. Blaylock’s Prescriptions for Natural Health.

“Vitamin C is cheap, natural, non-toxic and readily available,” Lisanti said, “so to have it as a potential weapon in the fight against cancer would be a significant step.”

Lead author Gloria Bonuccelli said, “Our results indicate it is a promising agent for clinical trials, and as an add-on to more conventional therapies, to prevent tumor recurrence, further disease progression and metastasis.”

The effectiveness of vitamin C in fighting cancer has been hotly debated. Laboratory studies found that vitamin C killed cancer cells in the laboratory and also in mice, but similar results haven’t always been supported in human studies.

Experts speculate that contrary to laboratory and mice studies, most human studies have been conducted using oral vitamin C, and most is unused and excreted in urine. “The dose of vitamin C has to be very high,” says Blaylock. Very high doses are usually reached by IV infusion.

Until now, researchers have also believed that vitamin C’s anti-cancer potential is due to its antioxidant capabilities. However, researchers at the University of Iowa also found that vitamin C may actually work by generating free radicals that literally tear cancer cells apart while avoiding healthy cells.

A study published in Science found that vitamin C caused oxidative stress in cancer cells and turned off an enzyme cancer cells use to reproduce.

Vitamin C has also been shown to be effective in other areas of health:

• An analysis of 29 randomized human studies by scientists at Johns Hopkins found that a 500 milligram tablet of vitamin C each day significantly reduced both systolic and diastolic blood pressure.

• A European study of almost 20,000 men and women found that mortality from cardiovascular disease was 60 percent lower in people with the highest concentrations of vitamin C in their blood when compared to those with the lowest concentrations.

• A study published in The American Journal of Clinical Nutrition found that men with the lowest blood levels of vitamin C had a 62 percent higher risk of cancer-related death after a 12 to 16 year period, compared to those with the highest vitamin C levels.

• A Finnish study, which was published in Allergy, Asthma & Clinical Immunology, found that vitamin C halved the incidence and duration of the symptoms of bronchoconstriction, which causes symptoms of asthma during exercise. It also increased the post-exercise capacity of the lung’s small airways by 50 to 150 percent in more than 40 percent of asthmatics.

Source : https://goo.gl/WL2KzQ

Dr. Anand Srivastava Meeting With Anupriya Patel Minister of State in the Ministry of Health and Family Welfare, Government of India About Stem Cell Therapy.

 

 

World-first Transplant to Treat Macular Degeneration Could Augur Rise of iPS Cell Banks

On March 28, a Japanese man in his 60s became the first person to receive cells derived from induced pluripotent stem (iPS) cells that had been donated by another person.

The surgery is expected to set the path for more applications of iPS cell technology, which offers the versatility of embryonic stem cells without the latter’s ethical taint. Banks of iPS cells from diverse donors could make stem cell transplants more convenient to perform, while slashing costs.

iPS cells are created by removing mature cells from an individual (from their skin, for example), reprogramming these cells back to an embryonic state, and then coaxing them to become a cell type useful for treating a disease.

In the recent procedure, performed on a man from Hyogo prefecture, skin cells from an anonymous donor were reprogrammed and then turned into a type of retinal cell that was transplanted onto the retina of the patient who suffers from age-related macular degeneration. Doctors hope the cells will stop progression of the disease, which can lead to blindness.

In a procedure performed in September 2014 at the Kobe City Medical Center General Hospital, a Japanese woman received retinal cells derived from iPS cells. They were taken from her own skin, though, and then reprogrammed. Such cells prepared for a second patient were found to contain genetic abnormalities and never implanted.

The team decided to redesign the study based on new regulations, and no other participants were recruited to the clinical study. In February 2017, the team reported that the one patient had fared well. The introduced cells remained intact and vision had not declined as would usually be expected with macular degeneration.

In today’s procedure — performed at the same hospital and by the same surgeon Yasuo Kurimoto — doctors used iPS cells that had been taken from a donor’s skin cells, reprogrammed and banked. Japan’s health ministry approved the study, which plans to enroll 5 patients, on 1 February.

Using a donor’s iPS cells does not offer an exact genetic match, raising the prospect of immune rejection. But Shinya Yamanaka, the Nobel Prize-winning stem-cell scientist who pioneered iPS cells, has contended that banked cells should be a close enough match for most applications.

Yamanaka is establishing an iPS cell bank, which depends on matching donors to recipients via three genes that code for human leukocyte antigens (HLAs) — proteins on the cell surface that are involved in triggering immune reactions. His iPS Cell Stock for Regenerative Medicine currently has cell lines from just one donor. But by March 2018, they hope to create 5-10 HLA-characterized iPS cell lines, which should match 30%-50% of Japan’s population.

Use of these ready-made cells has advantages for offering stem cell transplants across an entire population, says Masayo Takahashi, an ophthalmologist at the RIKEN Center for Developmental Biology who devised the iPS cell protocol deployed in today’s transplant. The cells are available immediately — versus several months’ wait for a patient’s own cells — and are much cheaper. Cells from patients, who tend to be elderly, might have also accumulated genetic defects that could increase the risk of the procedure.

At a press conference after the procedure, Takahashi said the surgery had gone well but that success could not be declared without monitoring the fate of the introduced cells. She plans to make no further announcements about patient progress until all five procedures are finished. “We are at the beginning,” she says.

Source : https://goo.gl/Jyim9B

-->

Liver Cirrhosis Treatment at GIOSTAR – Patient Testimonial

 

Mr. Vizar Ali Noor Mohammed, 60 years old was suffering with liver cirrhosis – patient testimonial and undergone stem cells treatment with us; through the recommendation of his relative. The patient visited us, all the way from his residence at Nagpur, Maharashtra. His pathological reports were clearly indicating very low levels of haemoglobin 11, platelets 24000 and Albumin 3.1; which straightaway reflect the possibility of liver failure.

However, within 10 months of his stem cells infusion sessions, he detected to be recovered very nicely. His platelet counts have been increased to 45000 and his albumin count has also improved to 4; thus exhibiting good recovery.

Hi, my name is Ali Noor Mohammed and I am from Nagpur, Maharashtra. I had been suggested stem cells therapy at GIOSTAR, for my Liver cirrhosis, by one of my relatives, who resides at Yawatmal, Maharashtra. From the very first day of my consultation till date; I found that doctors here are very experienced and co-operative. They are very positive and thoughtful; and the whole treatment was offered to me with a very positive attitude.

I am feeling much better, since my initial session and definitely would recommend the treatment to someone, who is suffering with Liver Disorders.

Make An Enquiry

We are here to help you

WordPress Video Lightbox